Norges Bank Arcellx, Inc. Transaction History

Norges Bank

$736 Billion
Q4 2024

A detailed history of Norges Bank transactions in Arcellx, Inc. stock. As of the latest transaction made, Norges Bank holds 27,251 shares of ACLX stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,251

Holding current value

$1.72 Million

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	BUY	$75.39 - $106.53 $2.05 Million - $2.9 Million	27,251 New	27,251 $2.08 Million
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $2.12 Million - $4.08 Million	123,600 New	123,600 $3.83 Million

Others Institutions Holding ACLX

# of Institutions

222

Shares Held

45.2M

Call Options Held

2.23M

Put Options Held

907K

Paradigm Biocapital Advisors LP New York, NY

4M
Shares

$253 Million
12.04% of portfolio
Perceptive Advisors LLC New York, NY

3.89M
Shares

$246 Million
8.48% of portfolio
Nea Management Company, LLC Timonium, MD

3.75M
Shares

$237 Million
23.89% of portfolio
Black Rock Inc. New York, NY

3.52M
Shares

$222 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

3.33M
Shares

$210 Million
0.0% of portfolio

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.77B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account